Alojz Bomba, DVM, DSc.


Head of Institute of Experimental Medicine, Faculty of Medicine of Pavol Jozef Šafárik University in Košice, Slovakia.

Research is focused on the prevention of chronic diseases by modulation of gut microbiota using probiotic micro-organisms and natural bioactive substances.

Member of Scientific Committee of the International Scientific Conference on Probiotics and Prebiotics, IPC2020. #probioticconference

The initiator of the potentiated probiotics concept and targeted gut microbiota modulation. Gnotobiotic expert. Author of 54 peer-reviewed scientific papers registered in CC; contributor of 4 textbook chapters.

Current knowledge suggests that gut microbiota and dysbiosis play an extraordinary role in disease pathogenesis and a better understanding of mechanisms of their involvement in health maintenance and disease development is needed.
Our research team develops an original solution of targeted gut microbiota modulation, which could be helpful in the prevention and treatment of diseases and could meet the criteria of a personalized medicine approach. Personalized medicine approach in gut microbiota modulation is based on analysis of patient´s gut microbiome that reveals the specific changes in his gut microbiota and allows to use of targeted and personalized gut microbiota modulation.
The main principle of the solution is to precisely analyse and cultivate the gut microbiota of the patient ex vivo subsequently modulate gut microbiota using beneficial microorganisms and substances potentiating their effects. The modified gut microbiota will be applied back to the patient.
This approach has a unique advantage because it eliminates the risks connected with fecal microbiota transplantation and it allows the targeted modulation according to the specific needs of the patient. The analysis of the patient´s gut microbiome and metabolome could also serve for the selection of suitable and effective probiotics and prebiotics for their preventive application.